Vetter Pharma Commits $243 Million Toward New Production Facility in Germany
CDMO’s goal is to increase building’s aseptic manufacturing capacity.
Vetter Pharma, a contract development and manufacturing organization (CDMO), is investing $243 million into its new production building, which is currently under construction at its global corporate headquarters site in Ravensburg, Germany. In an effort to increase aseptic manufacturing capacity, the building will feature several new commercial filling lines; the first cleanrooms will be installed by the end of 2024.
Additional investments include the increase of lab space for analytical services, the expansion of filling capacity through new commercial production lines at other sites in the EU, and the expansion in cool storage and warehousing, along with a new technical equipment warehouse.
“Our new production building signifies our ongoing dedication to support the needs of our customers concerning their complex injectable drug products with regards to packaging systems, specific process requirements and batch sizes,” says Thomas Otto, the CDMO’s managing director. “This is just one of several investments we are currently undertaking to manage our sustainable growth.”
